CD8A and colonic neoplasm: By combining this panel of genetically defined biomarkers that had previously been shown to be prognostic in stage II colon cancer [9], with the density of intratumoral T-cells (CD3/CD8), we aimed to predict the individual risk of metachronous metastasis, and response to 5-FU based adjuvant therapy in stage III colon cancer.